The FDA cleared an investigational new drug application for NTX-1024 ophthalmic solution in vernal keratoconjunctivitis, ...
Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced ...
Please provide your email address to receive an email when new articles are posted on . The acceptance paves the way for a pending phase 2b/3 clinical trial of COMP360 in PTSD. The manufacturer plans ...
The path from promising scientific insight to an Investigational New Drug (IND) application is both exhilarating and unforgiving. Regardless of how breakthrough the science may be, success depends on ...
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application from FluoGuide A/S in Copenhagen, Denmark, allowing the company to move forward in the U.S. with a ...
“Let it grow, let it blossom,” said Eric Clapton, and so the Food and Drug Administration expects of expanded access programs with the issuance of its guidance on “Expanded Access to Investigational ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ESTERO, FL / ACCESS Newswire / January 7, 2026 / Aspire Biopharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results